Praxis Precision Medicines partners with Remagine Labs for transdermal patch of ulixacaltamide

Praxis Precision Medicines, Inc.

Collaboration to develop iontophoretic transdermal patch for ulixacaltamide for essential tremor.
Remagine's platform enables precise, multi-day active transdermal dosing.
Praxis made an equity investment in Remagine to support program advancement.
Transdermal option intended to broaden patient population and strengthen competitive positioning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.